Administration of antioxidant compounds affects the lens chaperone activity and prevents the onset of cataracts

Yosuke Nakazawa, Noriaki Nagai, Nana Ishimori, Jun Oguchi, Hiroomi Tamura

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To prevent lens opacification and cataract formation, the lens contains α-crystallin, which has been shown to function as a molecular chaperone that maintains the correct folding of other proteins. Oxidative stress is known to be an important factor in the initiation and progression of a cataract. So far, several antioxidant compounds have been reported to prevent cataracts in vivo and in vitro. This stress also triggers α-crystallin modifications and alters its chaperone activity. However, few studies have examined the relationship between the consumption of antioxidant compounds and lens chaperone activity. To elucidate the effect of antioxidants on lens chaperone activity, antioxidants were administered to a selenite-induced cataract model of rats. The chaperone activity in lens water-soluble fraction was measured using aldehyde dehydrogenase. All antioxidant treatment groups, except decaffeinated coffee treatment, had less severe central opacities and lower stage cataracts than control groups. The chaperone activity was weaker in lens of selenite cataract rats, but antioxidant compounds and coffee treatment can prevent the chaperone activity decreasing, but not decaffeinated coffee. These results suggested that the treatment with antioxidant compounds could prevent cataract formation by the maintenance of the chaperone activity in water-soluble lens proteins. Thus, this study describes the development of an anticataract drug target for lens chaperone activity.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalBiomedicine and Pharmacotherapy
Volume95
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Cataract
Lenses
Antioxidants
Crystallins
Coffee
Selenious Acid
Peptide Initiation Factors
Aldehyde Dehydrogenase
Molecular Chaperones
Water
Protein Folding
Oxidative Stress
Maintenance
Control Groups
Pharmaceutical Preparations

Keywords

  • Anticataract
  • Antioxidant
  • Chaperone activity
  • Lens proteins

ASJC Scopus subject areas

  • Pharmacology

Cite this

Administration of antioxidant compounds affects the lens chaperone activity and prevents the onset of cataracts. / Nakazawa, Yosuke; Nagai, Noriaki; Ishimori, Nana; Oguchi, Jun; Tamura, Hiroomi.

In: Biomedicine and Pharmacotherapy, Vol. 95, 01.11.2017, p. 137-143.

Research output: Contribution to journalArticle

@article{44c89cfa7ed74b0dbb69c7eabcc874cb,
title = "Administration of antioxidant compounds affects the lens chaperone activity and prevents the onset of cataracts",
abstract = "To prevent lens opacification and cataract formation, the lens contains α-crystallin, which has been shown to function as a molecular chaperone that maintains the correct folding of other proteins. Oxidative stress is known to be an important factor in the initiation and progression of a cataract. So far, several antioxidant compounds have been reported to prevent cataracts in vivo and in vitro. This stress also triggers α-crystallin modifications and alters its chaperone activity. However, few studies have examined the relationship between the consumption of antioxidant compounds and lens chaperone activity. To elucidate the effect of antioxidants on lens chaperone activity, antioxidants were administered to a selenite-induced cataract model of rats. The chaperone activity in lens water-soluble fraction was measured using aldehyde dehydrogenase. All antioxidant treatment groups, except decaffeinated coffee treatment, had less severe central opacities and lower stage cataracts than control groups. The chaperone activity was weaker in lens of selenite cataract rats, but antioxidant compounds and coffee treatment can prevent the chaperone activity decreasing, but not decaffeinated coffee. These results suggested that the treatment with antioxidant compounds could prevent cataract formation by the maintenance of the chaperone activity in water-soluble lens proteins. Thus, this study describes the development of an anticataract drug target for lens chaperone activity.",
keywords = "Anticataract, Antioxidant, Chaperone activity, Lens proteins",
author = "Yosuke Nakazawa and Noriaki Nagai and Nana Ishimori and Jun Oguchi and Hiroomi Tamura",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.biopha.2017.08.055",
language = "English",
volume = "95",
pages = "137--143",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Administration of antioxidant compounds affects the lens chaperone activity and prevents the onset of cataracts

AU - Nakazawa, Yosuke

AU - Nagai, Noriaki

AU - Ishimori, Nana

AU - Oguchi, Jun

AU - Tamura, Hiroomi

PY - 2017/11/1

Y1 - 2017/11/1

N2 - To prevent lens opacification and cataract formation, the lens contains α-crystallin, which has been shown to function as a molecular chaperone that maintains the correct folding of other proteins. Oxidative stress is known to be an important factor in the initiation and progression of a cataract. So far, several antioxidant compounds have been reported to prevent cataracts in vivo and in vitro. This stress also triggers α-crystallin modifications and alters its chaperone activity. However, few studies have examined the relationship between the consumption of antioxidant compounds and lens chaperone activity. To elucidate the effect of antioxidants on lens chaperone activity, antioxidants were administered to a selenite-induced cataract model of rats. The chaperone activity in lens water-soluble fraction was measured using aldehyde dehydrogenase. All antioxidant treatment groups, except decaffeinated coffee treatment, had less severe central opacities and lower stage cataracts than control groups. The chaperone activity was weaker in lens of selenite cataract rats, but antioxidant compounds and coffee treatment can prevent the chaperone activity decreasing, but not decaffeinated coffee. These results suggested that the treatment with antioxidant compounds could prevent cataract formation by the maintenance of the chaperone activity in water-soluble lens proteins. Thus, this study describes the development of an anticataract drug target for lens chaperone activity.

AB - To prevent lens opacification and cataract formation, the lens contains α-crystallin, which has been shown to function as a molecular chaperone that maintains the correct folding of other proteins. Oxidative stress is known to be an important factor in the initiation and progression of a cataract. So far, several antioxidant compounds have been reported to prevent cataracts in vivo and in vitro. This stress also triggers α-crystallin modifications and alters its chaperone activity. However, few studies have examined the relationship between the consumption of antioxidant compounds and lens chaperone activity. To elucidate the effect of antioxidants on lens chaperone activity, antioxidants were administered to a selenite-induced cataract model of rats. The chaperone activity in lens water-soluble fraction was measured using aldehyde dehydrogenase. All antioxidant treatment groups, except decaffeinated coffee treatment, had less severe central opacities and lower stage cataracts than control groups. The chaperone activity was weaker in lens of selenite cataract rats, but antioxidant compounds and coffee treatment can prevent the chaperone activity decreasing, but not decaffeinated coffee. These results suggested that the treatment with antioxidant compounds could prevent cataract formation by the maintenance of the chaperone activity in water-soluble lens proteins. Thus, this study describes the development of an anticataract drug target for lens chaperone activity.

KW - Anticataract

KW - Antioxidant

KW - Chaperone activity

KW - Lens proteins

UR - http://www.scopus.com/inward/record.url?scp=85027864996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027864996&partnerID=8YFLogxK

U2 - 10.1016/j.biopha.2017.08.055

DO - 10.1016/j.biopha.2017.08.055

M3 - Article

VL - 95

SP - 137

EP - 143

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

ER -